LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that it has achieved a key milestone related to the second of three discovery programs under its collaboration with GlaxoSmithKline (NYSE:GSK). Using its proprietary, integrated computational-medicinal chemistry approach to drug discovery, EPIX has identified three lead candidates to move forward into lead optimization in this second G-protein coupled receptor (GPCR) discovery program. Under the collaboration, EPIX is entitled to receive a $3 million milestone payment from GSK in the next 30 days. In August, EPIX announced that it had identified three lead candidates for the first discovery program, which entitled the company to a $3 million milestone payment.
